Clinical trials: Propionibacterium
Acne Vulgaris, Acne
Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne
This is a Phase II, randomized, vehicle-controlled, double-blind, multi center study to evaluate the efficacy and safety of topically applied MBI 226 1.25% and 2.5% Acne Solutions as anti-acne preparations in human subjects with…
- Conditions
- Acne Vulgaris, Acne, Propionibacterium Acnes
- Trial name
- NCT00211497
- Testing
- MBI 226 Acne Solutions
- Volunteers
- 255 people
- Sponsor
- BioWest Therapeutics Inc
Acne
Evaluation and Detection of Facial Propionibacterium Acnes Bacteria and Phage
This multi-center, outpatient study will extract and evaluate the presence of facial P. acnes bacteria and phage strains using pore strips on up to 400 human subjects.
- Trial name
- NCT03009903
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- MBcure Ltd
Acne Vulgaris
A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel
This is a 2 week Phase 1 study of SB204 (NVN1000 Gel) in healthy adult volunteers with elevated Propionibacterium acnes (P. acnes) counts. Subjects will apply NVN1000 4% Gel or Vehicle Gel twice daily to their face.
- Trial name
- NCT01844739
- Testing
- NVN1000 4% Gel, Vehicle Gel
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novan, Inc.
Acne Vulgaris
Anti Propionibacterium(P.) Acnes Activity of Epiduo® Gel Compared to Benzoyl Peroxide (BPO) 2.5% Gel
The purpose of this study is to evaluate the antibacterial activity of Epiduo® Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel) on P. acnes compared to that of Benzoyl Peroxide 2.5% Gel.
- Trial name
- NCT01188538
- Testing
- Epiduo gel, BPO
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Galderma R&D
P Acnes Colonization
Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes
The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing antibiotic sensitive and resistant strains of P acnes in vivo.
- Trial name
- NCT00907101
- Testing
- Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne
Comparison of efficacy and safety of Azelaic Acid 15% gel with its vehicle in male and female patients with mild to moderate acne. Qualified subjects will apply the gel to their face twice a day for a period of 12 weeks.
- Trial name
- NCT00031096
- Testing
- Azelaic Acid Gel 15% (Finacea, BAY39-6251), Vehicle gel (SH H 655 PBA)
- Where
- 16 sites in United States
- Volunteers
- 879 people
- Sponsor
- LEO Pharma
Acne Vulgaris, Acne
Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne
This study investigates the safety and efficacy of MBI 226 2.5% and 5.0% Acne Solutions, applied topically for six weeks, in the treatment of acne.
- Conditions
- Acne Vulgaris, Acne, Propionibacterium Acnes
- Trial name
- NCT00211523
- Testing
- MBI 226 Acne Solutions
- Volunteers
- 75 people
- Sponsor
- BioWest Therapeutics Inc
Acne Vulgaris
Acne Vulgaris Related Microbiology and Serology
This will be an investigation to determine the quality of the serological immune responses against Propionibacterium acnes (P. acnes) in acne patients compared to healthy individuals.
- Trial name
- NCT04056598
- Testing
- Study of humoral immunity
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi
Acne Vulgaris
BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes
This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1%…
- Trial name
- NCT02709096
- Testing
- BPX-01, 1% Topical Gel, BPX-01 Vehicle Gel
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- BioPharmX, Inc.